Financial Performance - Full year 2024 total revenue was 37.7million,representinga39.3 million, up 18% compared to 7.9millioninthesamequarterofthepreviousyear[1][5]−RevenuefromLabEssentialsforthefullyear2024was28.9 million, largely unchanged from 28.8millionin2023[11]−ClinicalSolutionsrevenueforthefullyear2024was7.1 million, a 5% increase from 6.7millionin2023[11]OperationalHighlights−Thecompanyachieveda412.1 million, with a gross margin of 23.0%, compared to 17.0% in the fourth quarter 2023 [6][9] - Operating expenses for the fourth quarter 2024 were 7.8million,downfrom12.2 million in the fourth quarter 2023, primarily due to reduced headcount and spending [8] Cash Flow and Debt - Total cash and short-term investments at the end of fiscal year 2024 were 30.4million,withgrossdebtof12.1 million [7] - Free Cash Flow for the full year 2024 was negative 13.5million,animprovementfromnegative26.7 million in 2023 [15] - The company anticipates free cash outflow of less than 12millionfor2025[16]FutureOutlook−Thecompanyprovides2025revenueguidanceof39 million to $42 million [1][16] - Management expressed confidence in long-term sustainable growth due to the diversity of their catalog and custom research reagents [2]
